Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?

Basic & clinical pharmacology & toxicology - 1 Oct 2013

Herbild Louise, Andersen Stig E, Werge Thomas, Rasmussen Henrik B, Jürgens Gesche

Abstract excerpt

The effect of pharmacogenetic testing for CYP450 2D6 and 2C19 on treatment costs have not yet been documented. This study used Danish patient registers to calculate healthcare costs of treating patients with diagnoses within the schizophrenic spectrum for 1 year with or without pharmacogenetic testing for polymorphisms in the genes for the CYP2D6 and CYP2C19 enzymes. In a randomized, controlled trial, stratified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Denmark

Share to Health Care Costs

Share to Pharmacogenetics

Share to Schizophrenia

Share to Young Adult

Source

Identifiers

PMID: 23731498
DOI: 10.1111/bcpt.12093

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?PMID 23731498Read ↗

Towards the implementation ofCYP2D6andCYP2C19genotypes in clinical practice: Update and report from a pharmacogenetic service clinicSemantic proximity Read ↗

Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders.Semantic proximity Read ↗

Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?Semantic proximity Read ↗

CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.Semantic proximity Read ↗

Deletion of the CYP2D6 gene as a likely explanation for the serious side effects of the antipsychotic drug pimozide: a case reportSemantic proximity Read ↗

Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.Semantic proximity Read ↗

A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Semantic proximity Read ↗

Use of Combinatorial Pharmacogenomic Guidance in Treating Psychiatric Disorders:financial impact on a health planSemantic proximity Read ↗

CYP2D6 mutations and therapeutic outcome in schizophrenic patients.Semantic proximity Read ↗

Pharmacogenetic, drug-gene interaction, clinical, and sociodemographic determinants of frequent use of the healthcare system and its economic impactSemantic proximity Read ↗

Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).Semantic proximity Read ↗

Pharmacogenetic Testing in Depressed Patients and Interdisciplinary Exchange between a Pharmacist and Psychiatrists Results in Reduced Hospitalization Times.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.